Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C

• Published in: BMC cancer 2023-02, Vol.23 (1), p.175-175, Article 175
• Main Authors: El Sadda, Rana R, Elshahawy, Zahraa R, Saad, Entsar A
• Format: Article
• Language: English
• Subjects: AFP; Analysis; Animals; Antitumor activity; Ascorbic acid; Ascorbic Acid - therapeutic use; Aspirin; Aspirin - therapeutic use; BAX; Bax protein; Bilirubin; CA19.9; Cancer therapies; Carcinogenicity; Carcinoma, Hepatocellular - chemically induced; Carcinoma, Hepatocellular - drug therapy; Care and treatment; Caspase; Caspase-3; Caspase-8; Complications and side effects; Cytotoxicity; Diagnosis; Dosage and administration; Doxorubicin; Doxorubicin - therapeutic use; Drug dosages; Enzymes; Fibrosis; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Hepatoma; Humans; Interleukin 6; Laboratory animals; Liver; Liver cancer; Liver Neoplasms - chemically induced; Liver Neoplasms - drug therapy; Males; Metastases; p53; p53 Protein; Physiology, Pathological; Rats; Statistical analysis; Synergistic; Thioacetamide; Thioacetamide - adverse effects; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Tumor Suppressor Protein p53 - metabolism; Variance analysis; Vascularization; Vitamin C; Vitamins; α-Fetoprotein
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-10644-5

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, so we should be concerned and look for effective/less-harmful treatments than chemotherapeutics already clinically in application. Aspirin works well ''in conjunction'' with other therapies for HCC since aspirin can boost the sensitivity of anti-cancer activity. Vitamin C also was shown to have antitumor effects. In this study, we examined the anti-HCC activities of synergistic combination (aspirin and vitamin C) vs. doxorubicin on HCC-bearing rats and hepatocellular carcinoma (HepG-2) cells. In vitro, we evaluated IC and selectivity index (SI) using HepG-2 and human lung fibroblast (WI-38) cell lines. In vivo, four rat groups were used: Normal, HCC (intraperitoneally (i.p.) administered 200 mg thioacetamide/kg/twice a week), HCC + DOXO (HCC-bearing rats i.p. administered 0.72 mg doxorubicin (DOXO)/rat/once a week), and HCC + Aspirin + Vit. C (i.p. administered vitamin C (Vit. C) 4 g/kg/day after day concomitant with aspirin 60 mg/kg/orally day after day). We evaluated biochemical factors [aminotransferases (ALT and AST), albumin, and bilirubin (TBIL) spectrophotometrically, caspase 8 (CASP8), p53, Bcl2 associated X protein (BAX), caspase 3 (CASP3), alpha-fetoprotein (AFP), cancer antigen 19.9 (CA19.9), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) using ELISA], and liver histopathologically. HCC induction was accompanied by significant time-dependent elevations in all measured biochemical parameters except the p53 level significantly declined. Liver tissue architecture organization appeared disturbed with cellular infiltration, trabeculae, fibrosis, and neovascularization. Following drug medication, all biochemical levels significantly reversed toward normal, with fewer signs of carcinogenicity in liver tissues. Compared to doxorubicin, aspirin & vitamin C therapy ameliorations were more appreciated. In vitro, combination therapy (aspirin & vitamin C) exhibited potent cytotoxicity (HepG-2 IC of 17.41 ± 1.4 µg/mL) and more excellent safety with a SI of 3.663. Based on our results, aspirin plus vitamin C can be considered reliable, accessible, and efficient synergistic anti-HCC medication.